On February 24, 2021, Vividion Therapeutics, Inc., a biotechnology company utilizing novel discovery technologies to unlock high-value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, announced the completion of a $135 million Series C financing. Wilson Sonsini Goodrich & Rosati’s patents and innovations practice has represented Vividion since the company’s inception and advised the company in patent matters related to the financing.

The financing was co-led by new investors Logos Capital and Boxer Capital of Tavistock Group, with participation from additional new investors SoftBank Investment Advisers, Avoro Capital Advisors, funds and accounts managed by BlackRock, RA Capital Management, funds and accounts advised by T. Rowe Price Associates, Inc., Surveyor Capital (a Citadel company), Woodline Partners LP, Acuta Capital, and Driehaus Capital. Existing investors ARCH Venture Partners, BVF Partners L.P., Casdin Capital, Mubadala Capital, Nextech Invest, and Versant Ventures also participated in the round.

Vividion has integrated multiple emerging technologies into its platform that enable the company to discover and develop potential therapies for well-known but previously undruggable targets. The platform conveys the unique ability to: find unknown or cryptic functional pockets on high-value targets; interact with those pockets using its first-in-kind, proteome-trained covalent chemistry library; and ensure precise selectivity across the entire proteome with its industrial-scale chemoproteomics capabilities. Leveraging this platform, Vividion is advancing a pipeline of potent and selective small molecule therapies across a range of oncology and immunology indications.

The Wilson Sonsini team that advised Vividion on patent matters related to the financing includes partner Mike Hostetler, counsel Uale Taotafa, and patent agent Katrina Otrubova.

For more information, please see Vividion’s press release.